Trial Profile
A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 07 Nov 2018 Results of a post hoc analysis of NCT01618188, NCT02003677, NCT01934712, NCT02568280 and NCT01831765 assessing the PK of fast-acting Insulin Aspart versus free Insulin Aspart, published in the Clinical Pharmacokinetics
- 15 Feb 2017 Results of post hoc analysis from pooled data of six trials (NCT02035371, NCT01924637, NCT02131246, NCT02033239, NCT02003677 and NCT01618188) published in the Clinical Pharmacokinetics
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.